www.bioworld.com/articles/454740
Biotechnology Company Deals With Miscellaneous Companies: Dec. 14, 2006 - Feb. 21, 2007
Feb. 26, 2007
| Company* (Country; Symbol) | Company | Type/Product Area | Terms/Details (Date) |
| Anavex Life Sciences Corp.* | Alexandre Vamvakides | Agreement for rights to a portfolio of three patents and one patent application covering drug candidates targeting neurological diseases and cancer | Anavex agreed to pay for the development of the compounds by spending not less than $200,000 per year (1/31) |
| Debiopharm Group* (Switzerland) | Kirin Brewery Co. Ltd. (Japan) | Exclusive agreement for Debio-0719, an inhibitor of lysophosphatidic acid signaling | Debiopharm will manage and fund development before out-licensing to sales and marketing partners in all territories outside of Asia, where Kirin will maintain rights; Kirin will receive milestone payments and royalties (1/30) |
| Integrated Genomics Inc.* | Arla Foods amba (Denmark) | Agreement to sequence and analyze lactic acid bacterium | Financial terms were not disclosed (1/30) |
| Napo Pharmaceuticals Inc. (LSE:NAPL) | Nicholas Piramal India Ltd. (India) | Plant screening agreement to discover diabetes thera-peutic agents | The companies will jointly own all products developed (1/22) |
| New Life Scientific Inc. (OTC BB:NWLS) | N/A | Exclusive license agreement for two platform technologies allowing for the formulation of topical drugs | The first technology involves topical formulation of prostaglandins, which will be used to develop treatments for erectile dysfunction, female sexual arousal disorder and for wound healing; the second technology is designed for enhanced drug bioavailability and will be used to increase concentrations of drugs for skin and nail fungal infections and other indications (1/16) |
| Sequenom Inc. (SQNM) | Lenetix Medical Screening Laboratory Inc. | Partnership to develop and commercialize a non-invasive prenatal Rhesus D incompatibility test based on Sequenom patent rights and RT PCR methodology | Financial terms were not disclosed (1/29) |
| Notes: | |||
| * Private companies are indicated with an asterisk. N/A = Not available. | |||
| Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
| LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||